Randomized study to compare Paclitaxel/Topotecan vs. Cisplatin/Topotecan in patients with recurrent cervical cancer - AGO-Cervix-1 study

被引：0
|
作者：
Thiel, F. C. [1 ]
Hilpert, F. [2 ]
Rein, D. [3 ]
Liebrich, C. [4 ]
Fasching, P. A. [5 ]
Beckmann, M. W. [5 ]
机构：
[1] Univ Frauenklin Erlangen, Erlangen, Germany
[2] Univ Klinikum Schleswig Holstein, Klin Gynakol & Geburtshilfe, Kiel, Germany
[3] Univ Frauenklin, Dusseldorf, Germany
[4] Klinikum Stadt Wolfsburg, Frauenklin, Wolfsburg, Germany
[5] Univ Klinikums Erlangen, Frauenklin, Erlangen, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2008年 / 68卷
关键词：
cervical cancer; paclitaxel; recurrent; topotecan;
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [1] AGO-Cervix-1 study: A prospective, randomized phase III study to compare the effects of clitaxel and Topotecan to those of Cisplatin and Topotecan for treatment of patients with recurrent or persistent cervical cancer
    Thiel, F.
    Rein, D. T.
    Runnebaum, I. B.
    Petry, K. U.
    Fasching, P. A.
    Beckmann, M. W.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 (05) : 553 - 553
  • [2] Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer
    Gass, Paul
    Thiel, Falk C.
    Haeberle, Lothar
    Ackermann, Sven
    Theuser, Anna-Katharin
    Hummel, Nadine
    Boehm, Sibylle
    Kimmig, Rainer
    Reinthaller, Alexander
    Becker, Sven
    Hilpert, Felix
    Janni, Wolfgang
    Vergote, Ignace
    Harter, Phlipp
    Emons, Julius
    Hein, Alexander
    Beckmann, Matthias W.
    Fasching, Peter A.
    Poeschke, Patrik
    GYNECOLOGIC ONCOLOGY, 2024, 183 : 25 - 32
  • [3] AGO-cervix-1: prospective random phase-III-study in the comparison of the effectivity between Paclitaxel and topotecan and a therapy with topotecan and cisplatin in recurring or persistent cervical carcinoma
    Thiel, F.
    Kreienberg, R.
    Hilpert, F.
    Reinthaller, A.
    Hanker, L.
    Beckmann, M. W.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2009, 69 (05) : 465 - 465
  • [4] AGO-Cervix-1-Prospective randomized Phase-III-Study to Compare the Effectiveness between a Therapy with Paclitaxel and Topotecan, and a Therapy with Topotecan and Cisplatin in relapsed or persistent Cervical cancer.
    Thiel, F. C.
    Kreienberg, R.
    Hilpert, F.
    Reinthaller, A.
    Hanker, L.
    Fasching, P. A.
    Beckmann, M. W.
    ONKOLOGIE, 2010, 33 : 116 - 116
  • [5] Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma
    Tiersten, AD
    Selleck, MJ
    Hershman, DL
    Smith, D
    Resnik, EE
    Troxel, AB
    Brafman, LB
    Shriberg, L
    GYNECOLOGIC ONCOLOGY, 2004, 92 (02) : 635 - 638
  • [6] Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel
    Hoskins, P.
    Vergote, I.
    Cervantes, A.
    Tu, D.
    Stuart, G.
    Zola, P.
    Poveda, A.
    Provencher, D.
    Katsaros, D.
    Ojeda, B.
    Ghatage, P.
    Grimshaw, R.
    Casado, A.
    Elit, L.
    Mendiola, C.
    Sugimoto, A.
    D'Hondt, V.
    Oza, A.
    Germa, J. R.
    Roy, M.
    Brotto, L.
    Chen, D.
    Eisenhauer, E. A.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (20) : 1547 - 1556
  • [7] Randomized phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer.
    Sehouli, J
    Sommer, H
    Klare, P
    Stauch, M
    Zeimet, A
    Paulenz, A
    Renziehausen, K
    Keil, E
    Lichtenegger, W
    Oskay-Ozcelik, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 483S - 483S
  • [8] Management of Recurrent or Residual Cervical Cancer with Cisplatin and Topotecan Combination Therapy in a Palliative Setting: A Prospective Study
    Taba T.
    Barmon D.
    Begum D.
    Kataki A.C.
    Kamei H.
    Indian Journal of Gynecologic Oncology, 2018, 16 (4)
  • [9] The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer
    Moon, Ji Young
    Song, Ik-Chan
    Ko, Young Bok
    Lee, Hyo Jin
    MEDICINE, 2018, 97 (14)
  • [10] Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer
    Muneaki Shimada
    Shinya Sato
    Tetsuro Oishi
    Hiroaki Itamochi
    Junzo Kigawa
    Nobuhiro Takeshima
    Daisuke Aoki
    Yoichi Aoki
    Yoshihiro Nambu
    Kazunori Ochiai
    International Journal of Clinical Oncology, 2016, 21 : 969 - 974
12345